New cancer detection methods offer hope for detecting cancer earlier, when people may have more treatment options and better outcomes.
Multi-cancer early detection (MCED) methods look for signals of cancer from a single blood sample.
Some MCED tests are commercially available, but no MCED test is currently approved by the U.S. Food and Drug Administration (FDA).
Early detection matters, and understanding routine cancer screening and new methods like MCED testing can help you have informed conversations about your care.
Stage at diagnosis is not only a prognosis. For survivors, it is a lasting condition of life.
Sally WernerCEO, Cancer Support Community
Why Early Detection Matters
Finding cancer early is about more than survival. Data show that an earlier diagnosis can help people live longer and have a better quality of life. When cancer is found at an earlier stage, people tend to have more treatment options. They also tend to experience fewer or milder symptoms and less financial stress than people who are diagnosed at later stages.
Real-World Findings
Our research team at CSC surveyed 3,445 people with solid tumor cancers. We wanted to examine how experiences differ based on when someone’s cancer was diagnosed — and we did find differences.1
Compared to people diagnosed at later stages, patients with earlier diagnoses reported:
Feeling more prepared to make treatment decisions
Having more knowledge of treatment options and cost of treatment
Being more involved in their treatment decision making
Having less symptom burden and better quality of life
Experiencing less financial strain related to their cancer diagnosis
Relying less on savings, retirement funds, or fundraising to cover costs
Watch CSC's CEO Sally Werner speak before an FDA advisory committee on Sept. 23, 2026, about why earlier detection matters for everyone.
Cancer Support Community. (2026). The Benefits of Earlier Diagnosis: The Impact of Cancer Stage at Diagnosis on Patient Decision-Making, Financial Resilience, and Quality of Life. [Unpublished resource]
Tools for Early Detection
Newer tools, such as multi-cancer early detection (MCED) tests, may help find cancers that do not have routine screening options. MCED tests have the potential to detect many different cancers through a simple blood test. There are still questions about how early detection methods, including MCED tests, can work best, such as:
How to apply early detection methods in real-world settings
Ways to ensure follow-up care
Making early detection methods affordable and accessible
4 Things to Know About MCED Tests
1. Cancer screening tests, including MCED tests, look for cancer signals, but they cannot diagnose cancer on their own.
Cancer can’t be diagnosed with a single test. MCED testing can complement, but not replace, recommended cancer screening. The process of diagnosing cancer usually begins with a visit to a doctor. During the visit, the patient and doctor discuss symptoms, concerns, and personal and family health history. Then, the doctor may perform a physical exam and order tests, such as blood work and imaging scans, to look for signs of cancer. In some cases, a biopsy may be needed to collect a sample of tissue or cells for further testing of the suspected tissue or cells.2
2. Some cancers can be detected, but not all.
MCED tests are designed to detect signals associated with more than 50 types of cancer, but they cannot detect all 200-plus cancer types. Not all cancers can be detected through a blood test.3
Even though these tests do not find every type of cancer, they help fill the gaps in cancer screening, because not all cancers have routine screening tests or recommendations.
Some cancers, including breast, cervical, colorectal, lung, and prostate cancer, have routine screening methods and recommendations. For example, regular breast mammography is recommended for women starting at age 40 and regular colorectal screening for adults starting at age 45. These recommendations are meant for those at average risk and might change for those at higher risk based on family history or other factors.
Other cancers, including ovarian, pancreatic, and stomach cancer, do not have existing routine screening recommendations for people at average risk. Some of these cancers may be detected by MCED tests.3, 4 Because of this, MCED tests may find cancers that are often found only after symptoms appear.
3. MCED innovations are promising, but still growing.
MCED technology is a growing field. While some tests are commercially available, there is currently no MCED test authorized by the FDA (the U.S. Food and Drug Administration). Researchers are exploring:
How MCED methods can be used in real-world settings
Who benefits the most from these tests
How MCED testing can be used with existing cancer screening methods like mammograms and colonoscopies
4. MCED testing may not be appropriate for everyone.
MCED testing is generally accessed through a healthcare professional. People interested would need to speak with their healthcare provider about their personal risk factors and screening needs. The effects of MCED testing are still being studied. An MCED test may be appropriate for some people but may not be recommended or necessary for others.
National Cancer Institute. (2023, January 17). Tests and Procedures Used to Diagnose Cancer. https://www.cancer.gov/about-cancer/diagnosis-staging/diagnosis
U.S. Preventive Services Task Force. (n.d.). A and B Recommendations. https://www.uspreventiveservicestaskforce.org/uspstf/recommendation-topics/uspstf-a-and-b-recommendations
Understanding Cost, Follow-up Care, and Access
MCED testing is promising, but important factors should be considered, including cost, follow-up care, and access.
Cost
A healthcare provider may need to place an order or blood draw for MCED testing. Out-of-pocket costs can vary, and insurance coverage is not guaranteed. MCED tests are not diagnostic. So, if a patient receives a positive result, they may need to follow up with their doctor for laboratory testing or additional imaging.
In February 2026, the Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act (H.R. 842 and S. 339) was signed into law. The legislation allows for Medicare coverage and payment for FDA-approved MCED tests, starting on Jan. 1, 2028.5, 6 This gives beneficiaries access to new, breakthrough screening technologies that detect cancer at earlier stages.
Follow-up Care
MCED testing is not meant to replace recommended cancer screenings; it is intended to complement them. MCED tests are not perfect and may produce a false-positive result. People might experience a mix of emotions after receiving their results, so anyone planning to take a cancer detection test should be emotionally prepared. It is important to have a plan for follow-up care, regardless of the result.
Access
Finding cancer early can only be beneficial to everyone if everyone has fair access to it. Many communities face barriers to cancer screening and diagnosis, including:
Distance from care
Lack of insurance coverage
Transportation challenges
Language and cultural barriers
Limited access to medical specialists
People who have historically had less access to healthcare often find out they have cancer at a later stage, when it may be harder to treat. It is important for everyone to have fair access to testing, follow-up care, and treatment. Otherwise, existing differences in care may continue to grow.
As early detection methods advance, fair access remains one of the most important challenges. Recent federal policy developments may help address some of these barriers. Policymakers, healthcare providers, researchers, and patient advocacy organizations all play a role. These groups help decide if cancer detection tools are effective, affordable, accessible, and available to those who could benefit the most.
Looking Ahead
Researchers continue to learn about the future of early cancer detection. Research plays an important role because it can help clarify how promising new early detection methods may improve survival, quality of life, treatment experiences, and financial well-being — and how those benefits can reach everyone.
Arrington, J. C. (2025, January 31). H.R. 842—Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act. 119th Congress. https://www.congress.gov/bill/119th-congress/house-bill/842
